Industry spend on direct-to-consumer advertising for pharmaceuticals has returned to levels not seen in a decade.
Pharmaceutical manufacturers spent almost $6bn on DTC advertising in the US in 2015, nearly the same amount industry spent in...
DTC Advertising Is Back With A Bang
The pharmaceutical industry spent roughly $6bn in 2015 on direct-to-consumer advertising, and the upswing is expected to continue due to favorable economics. Most of the dollars go to TV ads, with more emphasis on targeted patient groups.
More from Business
• By
Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.
• By
While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.
• By
Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.
• By
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
More from Scrip
• By
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
• By
Oral RNA splicing modulator has gone into a Phase II/III trial
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program
• By
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.